• DVM360_Conference_Charlotte,NC_banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Listing
Conference Proceedings
Upcoming dvm360 Conferences
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
Veterinary Heroes
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

ACVIM 2017: Opportunistic Fungal Infections in Dogs With Immune-Mediated Diseases

August 5, 2017
Laurie Anne Walden, DVM, ELS

Researchers studying the incidence of opportunistic fungal infections in dogs being treated for immune-mediated disease were surprised by their findings.

Dogs receiving immunosuppressive treatment for immune-mediated diseases can develop opportunistic fungal infections (OFIs). These infections may cause small skin lesions or severe disseminated disease. The incidence of and risk factors for OFIs in dogs receiving immunosuppressive medications are currently not well understood.

In a poster presentation at the ACVIM Forum in June in National Harbor, Maryland, Brigitte McAtee, DVM, reported the results of a study of OFIs in dogs being treated for immune-mediated diseases. In this study, dogs receiving cyclosporine and male dogs were at increased risk for developing OFIs.

OFIs can be serious and are “something that clinicians need to look out for,” said Dr. McAtee, an internal medicine resident at Texas A&M University Veterinary Medical Teaching Hospital, in an interview with American Veterinarian®.

RELATED:

  • Dealing with Chronic Ear Infections In Dogs
  • Best Practices for Infection Control

Dr. McAtee and her colleagues conducted a retrospective study to investigate the incidence of OFIs in dogs receiving immunosuppressive therapy. Their secondary aim was to explore risk factors for OFI associated with particular immunosuppressive drugs.

The investigators reviewed the records of dogs seen at Texas A&M between January 2008 and December 2015. Dogs included in the study had immune-mediated hemolytic anemia, immune-mediated thrombocytopenia, immune-mediated polyarthritis, or Evans syndrome (concurrent immune-mediated hemolytic anemia and thrombocytopenia). Dogs were excluded from the analysis if they died or were lost to follow-up within 30 days of beginning immunosuppressive therapy.

Advertisement

The researchers analyzed the records of 246 dogs. Of these, 16 (6.5%) were diagnosed with an OFI. The percentage of dogs with fungal infections surprised the team, said Dr. McAtee. “It was kind of a shock for us.”

The most common immune-mediated disease in the study population was immune-mediated hemolytic anemia. Over half of the dogs included in the study had this condition.

In some dogs, fungal lesions were small and subtle. Other dogs developed large cutaneous ulcers. About half the lesions were described as nodules and half were described as ulcerative lesions (all cutaneous or subcutaneous).

One dog had only a single nodule on a distal extremity. A dog with multiple ulcerative nodules also had a renal capsule lesion caused by disseminated fungal infection; this dog died 6 days after diagnosis of the fungal infection.

The median time from initiation of immunosuppressive treatment to diagnosis of an OFI was 42.5 days (range, 7—390 days). Methods used to diagnose fungal infections included the following:

  • Skin lesion cytology alone: 5 dogs
  • Skin lesion cytology and culture: 4 dogs
  • Skin lesion culture and biopsy: 3 dogs
  • Skin lesion culture alone: 1 dog
  • Hair culture: 1 dog
  • Lymph node aspirate culture: 1 dog
  • Biopsy of renal capsule and dermal lesions: 1 dog

The dogs in the study were treated with prednisone, cyclosporine, and other immunosuppressive drugs. Dogs receiving cyclosporine were more than 4 times as likely to develop an OFI than those not receiving cyclosporine (odds ratio, 4.4; 95% CI, 1.2—16.2; P = .02).

Male dogs were significantly more likely than female dogs to have an OFI (odds ratio, 4.1; 95% CI, 1.4­­—12.4; P = .01). Dr. McAtee speculated that lifestyle factors might account for the sex difference, but the retrospective nature of the study did not allow for further investigation of possible explanations.

“Small, subtle nonulcerated/ulcerated cutaneous lesions may represent an OFI in dogs receiving immunosuppressive therapy,” conclude the study authors. They recommend that skin or subcutaneous lesions in these dogs be tested with cytology, culture, and/or histopathology.

Dr. Laurie Anne Walden received her doctorate in veterinary medicine from North Carolina State University. After an internship in small animal medicine and surgery at Auburn University, she returned to North Carolina, where she has been in small animal primary care practice for over 20 years. Dr. Walden is also a board-certified editor in the life sciences and owner of Walden Medical Writing, LLC. She works as a full-time freelance medical writer and editor and continues to see patients a few days each month.

Related Content:

Dermatology
Exploring molecular allergology as the future of allergy testing and immunotherapy
Exploring molecular allergology as the future of allergy testing and immunotherapy
dvm360® is seeking nominations for the 2023 Veterinary Heroes Awards
dvm360® is seeking nominations for the 2023 Veterinary Heroes Awards
New diet for canine atopic dermatitis management announced
New diet for canine atopic dermatitis management announced

Advertisement

Latest News

New technology and products for veterinary genealogy

Reduce your veterinary teams’ stress with financial wellness

Cuban crocodiles receive surgery to extract foreign items

Purina Pro Plan Veterinary Diets joins forces with AVMF

View More Latest News
Advertisement